Author

Asmus Tukundane

Observed name: A Tukundane

Institutions: James Lind Institute, Infectious Diseases Institute, Makerere University

Observed institutions: James Lind Institute, Infectious Diseases Institute, Makerere University

ORCID: 0009-0001-1444-8389

Observed ORCID: 0009-0001-1444-8389

OpenAlex ID: A5032382573

Cost-effectiveness of single, high-dose, liposomal amphotericin regimen for HIV-associated cryptococcal meningitis in five countries in sub-Saharan Africa: an economic analysis of the AMBITION-cm trial

2022 · David S Lawrence, Charles Muthoga, et al. · The Lancet Global Health · 34

Development and validation of quantitative PCR assays for HIV-associated cryptococcal meningitis in sub-Saharan Africa: a diagnostic accuracy study

2024 · Tshepiso Mbangiwa, Aude Sturny-Leclère, et al. · The Lancet Microbe · 17

Comparison of Early Fungicidal Activity and Mortality Between Daily Liposomal Amphotericin B and Daily Amphotericin B Deoxycholate for Cryptococcal Meningitis

2024 · Sarah Kimuda, Richard Kwizera, et al. · Clinical Infectious Diseases · 12

5-Flucytosine Longitudinal Antifungal Susceptibility Testing of Cryptococcus neoformans: A Substudy of the EnACT Trial Testing Oral Amphotericin

2023 · Thomas C McHale, Andrew Akampurira, et al. · Open Forum Infectious Diseases · 8

Inpatient initiation of tuberculosis preventive therapy with 1 month of isoniazid and rifapentine for adults with advanced HIV disease and cryptococcal meningitis (IMPROVE): a non-inferiority, randomised controlled trial

2026 · Jayne Ellis, Gila Hale, et al. · The Lancet HIV · 6

Diagnostic accuracy of the re-engineered urinary FujiLAM2 assay amongst hospitalized adults with advanced HIV disease

2025 · Jayne Ellis, Biyue Dai, et al. · AIDS · 5

Integrated management of cryptococcal meningitis and concurrent opportunistic infections to improve outcomes in advanced HIV disease: a randomised strategy trial

2024 · Jayne Ellis, Laura Nsangi, et al. · Wellcome Open Research · 5

Cerebrospinal Fluid Hypo-inflammation Drives Mortality in HIV-Associated Tuberculous Meningitis

2026 · Anna L Wilt, David B Meya, et al. · The Journal of Infectious Diseases · 4

Evaluating the Use of Lower Dose Flucytosine for the Treatment of Cryptococcal Meningitis: A Clinical Trial

2025 · Morris K Rutakingirwa, Caleb P Skipper, et al. · Clinical Infectious Diseases · 3

Prognostic Value of C-Reactive Protein in Adults With Tuberculous Meningitis: A Prospective Cohort Study

2025 · Lillian Tugume, Fiona V Cresswell, et al. · Clinical Infectious Diseases · 3

Investigation of human leukocyte antigen alleles as risk factors for cryptococcal disease in Ugandan individuals with HIV

2026 · Caleb P. Skipper, Biyue Dai, et al. · Human Immunology · 1

Once-Daily Dolutegravir–Based Antiretroviral Therapy Among Adults With Advanced HIV Disease Receiving 1 Month of Daily Rifapentine and Isoniazid for Tuberculosis-Preventive Therapy and Fluconazole for Treatment of Cryptococcal Meningitis: Results of a Pharmacokinetic Study

2026 · Jayne Ellis, Gila Hale, et al. · Open Forum Infectious Diseases

False-Positive IMMY® Serum Cryptococcal Antigen Lateral Flow Assay Results Due to Improper Use of Titration Buffer

2026 · Asmus Tukundane, Wilber Bakka, et al. · Journal of Fungi

Prevalence of CSF HIV VIRAL Escape and Associations With Neurocognitive Outcomes Among HIV-Associated Meningitis Survivors: A Cohort Study

2026 · Laura Nsangi, Gila Hale, et al. · Open Forum Infectious Diseases

The diagnostic role of elevated serum cryptococcal antigen titers in patients with suspected cryptococcal meningitis when lumbar puncture is contraindicated: A case report

2025 · Asmus Tukundane, Richard Kwizera, et al. · Medical Mycology Case Reports

Works count: 15

Citation count: 95

H-index: 5

I10-index: 3